UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $100 to $130.
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $100 to $130.